Natera initiated with a Buy at Citi

Citi initiated coverage of Natera (NTRA) with a Buy rating and $300 price target The company is an “established player” in the women’s and organ health markets, but its “dominant position” in the growing molecular residual disease market is the focus for investors, the analyst tells investors in a research note. Citi believes the shares warrant a premium multiple with a “significant” growth runway ahead for Natera.